Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 322-329

  Davidson, Michael H ^a   Voogt, Jason ^b   Luchoomun, Jayraz ^b   Decaris, Julie ^b   Killion, Salena ^b   Boban, Drina ^c   Glass, Alexander ^b   Mohammad, Hussein ^b   Lu, Yun ^b   Villegas, Deona ^b   Neese, Richard ^d   Hellerstein, Marc ^c,d   Neff, David ^e   Musliner, Thomas ^e   Tomassini, Joanne E ^e   Turner, Scott ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b KINEMED INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol absorption; Cholesterol efflux; Ezetimibe; Fecal sterols; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; LIPID ABSORPTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEROL EXCRETION;

CHOLESTEROL ABSORPTION; CHOLESTEROL EFFLUX; EZETIMIBE; FECAL STEROLS; REVERSE CHOLESTEROL TRANSPORT;

ABSORPTION; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL TRANSPORT; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; HYPERLIPIDEMIAS; INTESTINAL ABSORPTION; INTESTINES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEROLS;

EID: 84884509078     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.006     Document Type: Article

References (40)

1. Davis H.R., Tershakovec A.M., Tomassini J.E., Musliner T. Intestinal sterol transporters and cholesterol absorption inhibition. Curr Opin Lipidol 2011, 22:467-478.
2. Sudhop T., Lutjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
3. Sudhop T., Reber M., Tribble D., et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. JLipid Res 2009, 50:2117-2123.
4. Zetia [product insert] 2012, Merck & Co., Inc, Whitehouse Station, NJ.
5. Tremblay A.J., Lamarche B., Cohn J.S., Hogue J.C., Couture P. Effect of ezetimibe on the invivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006, 26:1101-1106.
6. Tremblay A.J., Lamarche B., Hogue J.C., Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. JLipid Res 2009, 50:1463-1471.
7. Sehayek E., Hazen S.L. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008, 28:1296-1297.
8. Briand F., Naik S.U., Fuki I., et al. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci 2009, 2:127-133.
9. Xie P., Jia L., Ma Y., et al. Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol 2013, 33:920-925.
10. Davis H.R., Lowe R.S., Neff D.R. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 2011, 215:266-278.
11. Salen G., Starc T., Sisk C.M., Patel S.B. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006, 130:1853-1857.
12. Turley S.D. The role of Niemann-Pick C1-Like 1 (NPC1L1) in intestinal sterol absorption. JClin Lipidol 2008, 2:S20-S28.
13. Kruit J.K., Groen A.K., van Berkel T.J., Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 2006, 12:6429-6439.
14. van der Velde A.E., Brufau G., Groen A.K. Transintestinal cholesterol efflux. Curr Opin Lipidol 2010, 21:167-171.
15. Turner S., Voogt J., Davidson M., et al. Measurement of reverse cholesterol transport pathways in humans: invivo rates of free cholesterol efflux, esterification, and excretion. JAm Heart Assoc 2012, 1:e001826.
16. Holleboom A.G., Jakulj L., Franssen R., et al. Invivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. JLipid Res 2013, 10.1194/jlr.P028449.
17. 2O) and mass isotopomer analysis. Am J Physiol 1994, 266:E372-E383.
18. 2)O: enabling back-to-back studies in the same subject. JLipid Res 2011, 52:1420-1428.
19. Schwartz C.C., Zech L.A., Vandenbroek J.M., Cooper P.S. Cholesterol kinetics insubjects with bile fistula. Positive relationship between size of the bileacid precursor pool and bile acid synthetic rate. JClin Invest 1993, 91:923-938.
20. Schwartz C.C., Vandenbroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output invivo in humans. JLipid Res 2004, 45:1594-1607.
21. Gomez-Garre D., Munoz-Pacheco P., Gonzalez-Rubio M., Aragoncillo P., Granados R., Fernandez-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009, 156:1218-1227.
22. Jakulj L., Trip M.D., Sudhop T., von Bergmann K., Kastelein J.J., Vissers M.N. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. JLipid Res 2005, 46:2692-2698.
23. Jakulj L., Vissers M.N., van Roomen C.P., et al. Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice. FEBS Lett 2010, 584:3625-3628.
24. deGoma E.M., Degoma R.L., Rader D.J. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. JAm Coll Cardiol 2008, 51:2199-2211.
25. Van Heek M., Compton D.S., Davis H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001, 415:79-84.
26. Ginsberg H.N. REVIEW: efficacy and mechanisms of action of statins in thetreatment of diabetic dyslipidemia. JClin Endocrinol Metab 2006, 91:383-392.
27. Assmann G., Kannenberg F., Ramey D.R., Musliner T.A., Gutkin S.W., Veltri E.P. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008, 24:249-259.
28. Repa J.J., Turley S.D., Quan G., Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. JLipid Res 2005, 46:779-789.
29. Salen G., von Bergmann K., Lutjohann D., et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004, 109:966-971.
30. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. NEngl J Med 2009, 361:2113-2122.
31. During A., Dawson H.D., Harrison E.H. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. JNutr 2005, 135:2305-2312.
32. Kasza I., Hegyi Z., Szabo K., et al. Model system for the analysis of cell surface expression of human ABCA1. BMC Cell Biol 2009, 10:93.
33. Labonte E.D., Howles P.N., Granholm N.A., et al. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Biochim Biophys Acta 2007, 1771:1132-1139.
34. Field F.J., Watt K., Mathur S.N. Ezetimibe interferes with cholesterol trafficking from the plasma membrane to the endoplasmic reticulum in CaCo-2 cells. JLipid Res 2007, 48:1735-1745.
35. Field F.J., Watt K., Mathur S.N. Origins of intestinal ABCA1-mediated HDL-cholesterol. JLipid Res 2008, 49:2605-2619.
36. Dietschy J.M. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr 1997, 65:1581S-1589S.
37. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
38. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
39. Califf R.M., Lokhnygina Y., Cannon C.P., et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010, 159:705-709.
40. Bays H.E., Neff D., Tomassini J.E., Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008, 6:447-470.